- Home
- LFVN vs IKT Comparison
LFVN vs IKT Comparison
Compare LFVN & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFVN
- IKT
- Stock Information
- Founded
- LFVN N/A
- IKT 2008
- Country
- LFVN United States
- IKT United States
- Employees
- LFVN N/A
- IKT N/A
- Industry
- LFVN Biotechnology: Pharmaceutical Preparations
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- LFVN Health Care
- IKT Health Care
- Exchange
- LFVN Nasdaq
- IKT Nasdaq
- Market Cap
- LFVN 165.9M
- IKT 139.0M
- IPO Year
- LFVN N/A
- IKT 2020
- Fundamental
- Price
- LFVN $13.05
- IKT $2.01
- Analyst Decision
- LFVN Strong Buy
- IKT Buy
- Analyst Count
- LFVN 2
- IKT 2
- Target Price
- LFVN $30.50
- IKT $8.00
- AVG Volume (30 Days)
- LFVN 215.9K
- IKT 123.6K
- Earning Date
- LFVN 05-06-2025
- IKT 05-14-2025
- Dividend Yield
- LFVN 1.38%
- IKT N/A
- EPS Growth
- LFVN 152.87
- IKT N/A
- EPS
- LFVN 0.70
- IKT N/A
- Revenue
- LFVN $222,347,000.00
- IKT N/A
- Revenue This Year
- LFVN $17.36
- IKT N/A
- Revenue Next Year
- LFVN $9.60
- IKT N/A
- P/E Ratio
- LFVN $18.62
- IKT N/A
- Revenue Growth
- LFVN 8.22
- IKT N/A
- 52 Week Low
- LFVN $5.22
- IKT $1.12
- 52 Week High
- LFVN $27.38
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- LFVN 51.11
- IKT 49.69
- Support Level
- LFVN $12.58
- IKT $1.70
- Resistance Level
- LFVN $13.53
- IKT $2.12
- Average True Range (ATR)
- LFVN 0.72
- IKT 0.19
- MACD
- LFVN 0.13
- IKT 0.01
- Stochastic Oscillator
- LFVN 74.22
- IKT 54.39
About LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.